Group | p | ||
| C | P | |
First stage |
|
|
|
IgA, µg/mL | 30.85 ± 2.07 | 33.82 ± 2.11 | 0.35 |
IgG, µg/mL | −104.69 ± 9.76 | −112.26 ± 8.67 | 0.58 |
IL-1β, ng/mL | 17.82 ± 1.74 | 11.98 ± 2.14 | 0.08 |
TNF-α, ng/mL | 3.33 ± 5.62 | 3.63 ± 2.67 | 0.96 |
IL-4, ng/L | 47.93 ± 1.98 | 0.00 ± 0.79 | <0.01 |
IL-6, ng/L | 2.98 ± 0.53 | 2.51 ± 0.16 | 0.42 |
IFN-γ, ng/L | −280.13 ± 33.20 | −224.76 ± 22.38 | 0.22 |
GH, µg/L | −1.08 ± 0.43 | −3.61 ± 0.28 | <0.01 |
LP, µg/L | −0.40 ± 0.18 | 1.48 ± 0.14 | <0.01 |
Second stage |
|
|
|
IgA, µg/mL | 2.455 ± 1.23 | 0.70 ± 0.47 | 0.23 |
IgG, µg/mL | −1.89 ± 57.51 | 65.45 ± 9.68 | 0.29 |
IL-1β, ng/mL | 9.46 ± 2.64 | 10.60 ± 2.85 | 0.78 |
TNF-α, ng/mL | 9.09 ± 5.07 | 9.17 ± 3.15 | 0.99 |
IL-4, ng/L | −41.86 ± 1.29 | −45.35 ± 4.54 | 0.49 |
IL-6, ng/L | 7.31 ± 0.45 | 7.46 ± 0.08 | 0.76 |
IFN-γ, ng/L | 153.00 ± 20.55 | 108.35 ± 28.19 | 0.25 |
GH, µg/L | −0.12 ± 0.17 | 0.71 ± 0.47 | 0.15 |
LP, µg/L | 0.08 ± 0.34 | 0.90 ± 0.27 | 0.11 |